Evidence map›Paper›PMID 34070898›Full record

ArticleGenes2021

Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies.

Sorina Mihaela Papuc, Alina Erbescu, Diana Cisleanu, Diana Ozunu, Cristina Enache, Ion Dumitru, Elena Lupoaia Andrus, Mihaela Gaman, Viola Maria Popov, Maria Dobre and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Sorina Mihaela PapucVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Alina ErbescuVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Diana CisleanuCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Diana OzunuVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Cristina EnacheCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Ion DumitruEmergency Universitary Clinical Hospital, 050098 Bucharest, Romania.
Elena Lupoaia AndrusCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Mihaela GamanCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Viola Maria PopovColentina Clinical Hospital, 020125 Bucharest, Romania.ORCID 0000-0002-1200-379X
Maria DobreVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Oana StancaCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Silvana AngelescuCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Nicoleta BerbecCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Andrei ColitaCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Ana-Maria VladareanuCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Horia BumbeaCarol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Aurora ArghirVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROInstitutul National Victor Babes · ROClinical Emergency Hospital Bucharest · ROSpitalul Clinic Colentina · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by a wide range of genetic defects. Cytogenetics, molecular and genomic technologies have proved to be helpful for deciphering the mutational landscape of AML and impacted clinical practice. Forty-eight new AML patients were investigated with an integrated approach, including classical and molecular cytogenetics, array-based comparative genomic hybridization and targeted next generation sequencing (NGS). Various genetic defects were identified in all the patients using our strategy. Targeted NGS revealed known pathogenic mutations as well as rare or unreported variants with deleterious predictions. The mutational screening of the normal karyotype (NK) group identified clinically relevant variants in 86.2% of the patients; in the abnormal cytogenetics group, the mutation detection rate was 87.5%. Overall, the highest mutation prevalence was observed for the

Indexed as

Mutation RateDNA Copy Number VariationsDNA Methyltransferase 3Afms-Like Tyrosine Kinase 3Genetic TestingGTP PhosphohydrolasesHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansLeukemia, Myeloid, AcuteMembrane ProteinsMyeloid-Lymphoid Leukemia ProteinNucleophosminDNA Methyltransferase 3ADNMT3A protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3GTP PhosphohydrolasesHistone-Lysine N-MethyltransferaseKMT2A protein, humanMembrane ProteinsMyeloid-Lymphoid Leukemia ProteinNPM1 protein, humanNRAS protein, humanNucleophosminchromosomal abnormalitiescopy number variantsdetection yieldmutational screeningsomatic mutations

Identifiers

PMID34070898
PMCPMC8229708
OpenAlexW3164233308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.